- Policy
- NHIS "providing reliable and reasonably priced generics"
- by Lee, Hye-Kyung Dec 30, 2019 06:19am
- Korea’s National Health Insurance Service (NHIS) has reported it would take over the generic management from next year. The Price-volume Agreement (PVA) system currently limited to new drug only would be also applied on generic pricing negotiation. The government agency plans to form a task force team to support Ministry of Health and Welfa
- Policy
- 'Brakes' on reimbursed drug’s listing process
- by Lee, Hye-Kyung Dec 27, 2019 06:27am
- This year, the insurance authorities were able to reorganize their drug price system to the organization of the person in charge of drug prices. Last year, The NHIS chairman Yong-ik Kim, who designed Moon Jae-in Care, was very active, and this year, there have been a number of institutional improvements that have been carried out by sta
- Policy
- Severe atopic drug Dupixent listed, first benefit from RSA
- by Kim, Jung-Ju Dec 26, 2019 06:34am
- Sanofi Aventis' treatment for severe atopic dermatitis, Dupixent PFS 300mg (Dupilumab), will be listed next month after all of its reimbursment hurdles. Although it was not an anticancer drug or a rare disease treatment agent, there was a difficulty in expanding the RSA, but the government and the health authorities were able to follow thi
- Policy
- Unpaid medical benefits “fully solved next month”
- by Kim, Jung-Ju Dec 26, 2019 06:31am
- The government reflected the unpaid medical benefits in the budget of &8361;100 billion in next year's budget. Most of this year's unpaid payments have been resolved, and the unpaid payments of nursing institutions, which appeared at the beginning & the end of the year, are being resolved somewhat. However, dues are reflected in next year's
- Policy
- Moon Care on new drug and generic pricing in 2019
- by Kim, Jung-Ju Dec 26, 2019 06:29am
- The Moon Jae-in administration’s ambitious Moon Jae-in Care has directly affected the drug pricing system, essential to the insurance coverage. The healthcare coverage enhancement policy lowered the threshold of new drug listing standard, but further complicated the post-marketing drug pricing system. Also Ministry of Health and Welf
- Policy
- Korea’s Drug expense management to settle on ‘trade-off’
- by Lee, Hye-Kyung Dec 24, 2019 06:10am
- Apparently, the government is to redirect finance saved by dropping drug with unproven clinical efficacy from reimbursement listing and adjusting drug price to provide coverage on new drugs for treating severe and rare disease. It would mean that the ‘trade-off’ strategy kept mentioned by Korea’s Ministry of Health and Welfare (MOHW), as
- Policy
- Moon Jae-in Care needs speed control
- by Lee, Hye-Kyung Dec 23, 2019 06:29am
- There were voices of concern that the government's policy to strengthen health insurance guarantees could weaken domestic economic growth potential and national competitiveness. The Korea Employers Federation (Chairman of KEF, Kyung-sik Sohn) held a session on the 19th to evaluate the 1st National Health Insurance Comprehensive Plan (2019 ~ 2
- Policy
- Who holds the key to end financial toxicity?
- by Lee, Hye-Kyung Dec 22, 2019 09:52pm
- Doctor: “Although it’s non-reimbursed, the immunotherapy option is recommended for kidney cancer. But it’s expensive” Patient: “How much is it?” Doctor: “It’s about 10 million won per month”. Patient: “Can I get fully recovered”. Doctor: “It’s not guaranteed”. Patient: “It’s too expensive”. Doctor: “Discuss and decide
- Policy
- Only one case of non-tumor initial human administration test
- by Lee, Tak-Sun Dec 20, 2019 06:35am
- Among the clinical trials conducted by multinational pharmaceutical companies in Korea, the first human-administered trial was found to be very rare. According to the Korea Clinical Trial White Paper No. 2 published by the Korea National Enterprise for Clinical Trials (CEO Dong-Hyun Ji, KoNECT) on the 18th, there was only one initial human d
- Policy
- Parliament pushes for drug revocation bill w/o sales record
- by Lee, Jeong-Hwan Dec 20, 2019 06:35am
- A bill was proposed by the National Assembly to prohibit the renewal of drug items without sales records. The legislative goal is to minimize damage to Valsartan-Ranitidine impurities (NDMA) by eliminating drugs that some pharmaceutical companies produce only the minimum quantity and do not sell in order to update the product, which is a p
